Resverlogix Corp. (RVXCF)
| Previous Close | 0.0380 |
| Open | 0.0416 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0416 - 0.0416 |
| 52 Week Range | 0.0300 - 0.1100 |
| Volume | |
| Avg. Volume | 9,511 |
| Market Cap | 12.021M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Resverlogix Announces Change to Its Board of Directors
Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said Donald McCaffrey, Resverlogix's President and CEO. About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal ...
- Newsfile
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation," by Dr. Sylwia Wasiak and colleagues, in Translational Neuroscience. This publication marks the 40th peer-reviewed scientific journal article published by Resverlogix researchers on apabetal
- Newsfile
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in the journal Biomedicines."The beneficial effect of apabetalone highlighted in these models of facioscapulohumeral muscular dystrophy in combination with the impressive clinical and safety data in met
